Revance Celebrates Distribution of One Million Vials of Daxxify in the U.S.
Revance recently announced that it has distributed one million vials of Daxxify (daxibotulinumtoxinA-lanm) for aesthetics in the U.S. This achievement comes only three years after the product’s FDA approval and highlights the position Daxxify plays as the fastest-growing neurotoxin in the country.
The neuromodulator Daxxify uses a proprietary peptide formulation and is made without human or animal-based components. It has a unique clinical profile that combines a fast onset with the ability to smooth even the deepest lines and deliver long-lasting results.
“Reaching the one million vial mark represents an important milestone in the advancement of aesthetic medicine and of DAXXIFY®,” says Conor Gallagher PhD, Chief Scientific Officer of Revance in a press release. “This achievement highlights the trust our provider partners place in our peptide formulated neurotoxin and reflects the value they place in innovation that translates into true clinical outcomes. We are encouraged by the growing body of real-world experience, and we are actively continuing to expand the science and data supporting DAXXIFY®.”
This milestone comes at a time when patients are more discerning than ever about ingredients in both the products and med spa treatments they select.
Learn more at Revance.com and DAXXIFY.com.
